财务数据和关键指标变化 - 第一季度收入为12.05亿美元,报告和同比货币基准下降4% [41] - 毛利率下降350个基点至57.3%,主要受ERP系统切换和通胀影响 [45] - 调整后EBITDA为2.94亿美元,同比受ERP系统切换影响下降 [44] - 调整后每股收益为0.34美元,同比受ERP系统切换影响下降 [48] - 经营活动现金流改善1.47亿美元,主要得益于存货和项目支出的减少 [50] 各条业务线数据和关键指标变化 - 宠物健康业务同比货币基准下降5%,受ERP系统切换影响 [42][43] - 农场动物业务同比货币基准下降3%,受ERP系统切换影响 [44] - 美国宠物健康业务同比下降8%,受ERP系统切换影响 [42] - 美国农场动物业务同比增长8%,受Experior等产品需求增加推动 [44] - 国际宠物健康业务同比下降3%,受ERP系统切换影响 [43] - 国际农场动物业务同比下降8%,受亚洲猪业疲软影响 [44] 各个市场数据和关键指标变化 - 美国市场宠物健康业务同比下降8%,受ERP系统切换和天气等因素影响 [42] - 美国市场农场动物业务同比增长8%,受Experior等产品需求增加推动 [44] - 国际市场宠物健康业务同比下降3%,受ERP系统切换影响 [43] - 国际市场农场动物业务同比下降8%,受亚洲猪业疲软影响 [44] 公司战略和发展方向及行业竞争 - 公司保持聚焦于增长、创新和现金流的战略,第三个季度连续交出不错的业绩 [166] - 公司现有创新产品销售势头良好,2023年贡献1亿美元,预计2024年将达3.75-4.1亿美元 [30][31] - 公司即将推出的3款重磅创新产品(Zenrelia、Credelio Quattro和Bovaer)有望在2024年下半年为公司带来收入贡献 [31][32][35][36] - 公司正在加强与大型宠物医疗机构的合作,提升品牌影响力和渠道渗透 [19] - 公司在宠物驱虫市场保持领先地位,正在采取多项措施提升市场份额 [16][17] 管理层对经营环境和未来前景的评论 - 公司第一季度业绩超出预期,体现了公司多元化产品组合和地域布局的优势 [10] - 公司对即将推出的3款重磅创新产品的审批和上市时间表充满信心 [11][32][33][34][35] - 公司预计2024年全年同比货币基准收入增长2%-3%,调整后EBITDA和每股收益也有所提升 [13][52][54] - 公司对未来发展前景保持乐观,认为创新产品和基础业务的增长动力足以支撑公司在2024年和未来几年实现良好表现 [60][62][166] 问答环节重要的提问和回答 问题1 **Jon Block 提问** 询问公司OTC驱虫产品市场疲软的原因,以及公司在该市场的份额表现 [68] **Jeff Simmons 回答** 公司OTC驱虫产品市场表现仍然强劲,受到天气等因素的短期影响,但公司采取的渠道拓展和营销策略正在发挥作用,带动销售增长 [69][70][71] 问题2 **Erin Wright 提问** 询问公司在即将推出的创新产品上的投入成本预算,以及对这些产品上市时间的确定性 [78][79] **Jeff Simmons 和 Todd Young 回答** 公司在创新产品上市前的营销投入尚未包含在指引中,但预计这些投入不会对EBITDA产生负面影响。公司对这些产品的审批时间表非常确定,正在与FDA保持良好沟通 [80][81][82][83] 问题3 **Michael Ryskin 提问** 询问公司即将推出的创新产品在市场上面临的竞争态势,以及Kexxtone产品在欧洲市场的情况 [90][91] **Jeff Simmons 回答** 公司已做好充分准备应对竞争,包括提升销售团队实力、优化产品标签差异化等。Kexxtone产品由于生产工艺问题已暂时下市,预计2025年底前能够重新上市 [92][93][94][100][101][102]

Elanco Animal Health Incorporated (ELAN) reported $1.21 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 4.1%. EPS of $0.34 for the same period compares to $0.45 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.17 billion, representing a surprise of +2.69%. The company delivered an EPS surprise of +30.77%, with the consensus EPS estimate being $0.26.While investors closely watch year-over-year changes in headline numbers -- revenue a ...

公司业务 - Elanco是一家全球动物健康领域的领导者，产品销往90多个国家，主要服务于狗、猫、牛、禽、猪、羊和水产等多种动物[78] - Elanco的产品组合约有200个品牌，帮助成为宠物主人、兽医和农场动物生产商的信任合作伙伴[79] - Elanco计划出售水产业务给Merck Animal Health，预计售价为13亿美元，将用于加速偿还债务和降低杠杆率[82] 公司收购与重组 - 2023年，Elanco完成了对NutriQuest和Bayer Animal Health业务的收购和整合，相关成本达9300万美元，影响了财务表现[81] - Elanco进行了重组计划，预计将裁员约420人，预计年度节省3000万至3500万美元[86] 全球宏观经济影响 - 全球宏观经济因素对Elanco的运营产生影响，包括俄乌冲突、供应链中断、汇率波动和通货膨胀等[87] 2024年第一季度财务表现 - Elanco的宠物健康业务在2024年第一季度收入下降5%，主要受到ERP系统整合的影响，导致销售额转移[95] - Elanco的农场动物业务在2024年第一季度收入下降3%，主要受到ERP系统整合的影响和中国猪业市场疲软的影响[96] - Elanco的销售成本在2024年第一季度增加4%，占收入比例从39%上升至43%，主要受到通货膨胀和产品组合影响[97] - Elanco的研发支出在2024年第一季度增加7%，主要受到员工相关费用和项目成本时间安排的影响[98] - 2024年第一季度，市场、销售和行政支出为3.37亿美元，同比增长3%[99] - 2024年第一季度，无形资产摊销为1.33亿美元，同比下降1%[100] - 2024年第一季度，资产减值、重组和其他特殊费用为4.6亿美元，同比增长15%[101] - 2024年第一季度，利息支出净额为6.6亿美元，同比增长3%[102] - 2024年第一季度，其他费用净额为0.9亿美元，持平[103] - 2024年第一季度，所得税费用为负20亿美元，较去年同期的5亿美元有所改善[105] 现金流及资产情况 - 截至2024年3月31日，公司现金及现金等价物为3.45亿美元，未使用的信贷额度约为5.5亿美元[107] - 2024年第一季度，经营活动现金流为2百万美元，较去年同期的负1.45亿美元有所改善[109] - 2024年第一季度，投资活动现金流为3.7亿美元，较去年同期的负5.5亿美元有所改善[110]

2024 Earnings – First Quarter May 8, 2024 2024 | Q1 Earnings Notices and Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2024 full year and second quarter guidance and long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance and f ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports First Quarter 2024 Results • First Quarter 2024 Financial Results ◦ Revenue of $1,205 million ◦ Reported Net income of $32 million, Adjusted Net income of $167 million ◦ Adjusted EBITDA of $294 million, or 24.4% of Revenue ◦ Reported EPS of $0.06, Adjusted EPS of $0.34 ◦ Net leverage r ...

Wall Street analysts forecast that Elanco Animal Health Incorporated (ELAN) will report quarterly earnings of $0.26 per share in its upcoming release, pointing to a year-over-year decline of 42.2%. It is anticipated that revenues will amount to $1.17 billion, exhibiting a decline of 6.6% compared to the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraise ...

Launches first-ever tracking site for often-fatal parvovirus outbreaks to Save 1 Million Puppies by 2030 GREENFIELD, Ind., April 23, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today unleashed a multi-faceted educational campaign – declaring today as the first-ever National Parvo Awareness Day, aimed at bringing awareness to this devastating and often-fatal puppy disease. As part of this effort, Elanco is releasing Parvo is Poop – an eye-catching campaign highlighting the way the vir ...

GREENFIELD, Ind., April 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco ...

New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthc ...

GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made i ...